<DOC>
	<DOC>NCT01309932</DOC>
	<brief_summary>The purpose of this study is to determine if combination therapy with Pegylated Interferon Lambda (BMS-914143) plus Ribavirin (RBV) with a single direct antiviral agent (BMS-790052 or BMS-650032) for 24 weeks is effective and safe for treatment of Chronic Hepatitis C (CHC) compared to current standard therapy with Pegylated Interferon Alpha-2a plus RBV for 48 weeks.</brief_summary>
	<brief_title>Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin</brief_title>
	<detailed_description>Study Classification: Pharmacokinetics/ Pharmacodynamics</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com. Chronic Hepatitis C, Genotype 1 HCV RNA &gt;100,000 IU/mL at screening; Seronegative for Human immunodeficiency virus (HIV) and Hepatitis B surface antigen (HBsAg); Liver biopsy within prior 2 years; subjects with compensated cirrhosis can enroll and will be capped at approximately 10% Any evidence of liver disease other than HCV; Coinfection with HIV; Diagnosed or suspected hepatocellular carcinoma; Medical history or laboratory value abnormalities that would prohibit the use of Pegylated Interferon Alpha2a or Ribavirin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>